天坛生物：公司持续深化生产精细化管理

Core Viewpoint - TianTan Biological announced on November 18 that the collection of blood plasma is expected to reach approximately 2,781 tons in 2024, representing a year-on-year increase of 15.15% [2] Group 1: Production and Management - The company emphasized that the process from blood plasma collection to sales revenue involves several steps, including quarantine, production, inspection, and batch release, which require a certain time cycle [2] - The company is committed to deepening refined management in production and strictly executing production plans to ensure maximum utilization of collected plasma and timely delivery of products [2] Group 2: Market Expansion - The company is enhancing market development efforts to improve product terminal coverage and increase product sales [2]